

ELEGANCE Registry: Data Continues to Show Eluvia is The Standard in SFA Stenting



New 12-month results for nearly 400 Eluvia™ DES in femoropopliteal lesions showed consistently strong outcomes, including in complex patients who typically carry the greatest risk: diabetic, chronic total occlusions, long lesions, or heavy calcium.

COMPLEX PATIENT SUB-ANALYSIS

Medically Treated
Diabetes Mellitus (DM)
N=195

Chronic Total Occlusion (CTO)
N=240


Long Lesions (LL) ≥150mm
N=135

Mod/Sev Calcium (Ca+)
N=241

Patients treated with Eluvia showed consistently positive 12-month outcomes, despite expectations in complex sub-groups typically at greater risk of complications or reinterventions.


93.2% Overall Primary Patency at 12 Months

12 MONTH K-M PRIMARY PATENCY Femoropopliteal lesions




94.1% Overall Freedom From CD-TLR

12 MONTH FREEDOM FROM CD-TLR Femoropopliteal lesions



99.4 % Overall Freedom From Major Amputations

12 MONTH FREEDOM FROM MAJOR AMPUTATION Femoropopliteal lesions



RANDOMIZED TRIALS SHOW WHAT A DEVICE CAN DO. REAL-WORLD EVIDENCE SHOWS WHAT IT DOES FOR THE PATIENTS IN FRONT OF YOU.

What is the ELEGANCE Registry?

POST MARKET REGISTRY

Non-randomized, Prospective,
Global, Mutli-center

DIVERSE ENROLLMENT

OBJECTIVE

≥ 40% Women
≥ 40% URM

TREATMENT TARGET

Lesions in peripheral
arterial circulation

EVALUATION &

FOLLOW-UP

Per site and treating
physician standard of care

PATIENT CHARACTERISTICS

N=382 PATIENTS

Female	28.8%
Race/Ethnicity	
Under-represented minorities	67.0%
Non-Hispanic White	33.0%
History of smoking	66.6%
Diabetes mellitus (DM), current	55.7%
Renal Insufficiency	15.5%
Baseline Rutherford Classification (RC)	
RC1	3.0%
RC2	11.0%
RC3	49.7%
RC4	16.1%
RC5	18.5%
RC6	1.6%
	CLTI 36.3%

LESION CHARACTERISTICS

N=405 Lesions

De novo	88.6%
In-Stent Restenosis (ISR)	5.9%
Location Involvement	
SFA	98.3%
Proximal Popliteal	14.3%
CTO	61.5%
Lesion ≥150 mm	33.3%
Lesion Length Treated (mm)	137.3 ± 85.2
Mod/Sev Calcium	63.9%
Stenosis	
Pre-treatment	93.9 ± 10.4
Post-treatment	6.0 ± 10.1
Vessel Preparation	
Atherectomy	4.9%
IVL	5.4%

12-MONTH OUTCOMES

N=382 PATIENTS, 405 LESIONS

Primary patency ^a	93.2 ± 1.3%
Freedom from CD-TLR ^a	94.1 ± 1.2%
Freedom from major amputation ^a	99.4 ± 0.4%
RC improvement ≥1 without TLR ^b	75.6%

Data are presented as % or mean ± SD

^aKaplan Meier analysis, ± SE

^b% (n/N)

COMPLEX SUB-GROUP LESION CHARACTERISTICS

DIABETES MELLITUS

N=208 Lesions

CTO

N=249 Lesions

LONG LESIONS ≥150 MM

N=135 Lesions

MOD/SEV CALCIUM

N=253 Lesions

De novo	88.5%	90.8%	92.6%	91.3%
In-Stent Restenosis (ISR)	6.3%	6.8%	5.2%	3.6%
Location Involvement				
SFA	97.6%	100.0%	100.0%	98.4%
Proximal Popliteal	15.9%	14.9%	15.6%	14.2%
CTO	58.7%	100.0%	82.2%	61.7%
Lesion ≥150 mm	28.8%	44.6%	100.0%	36.8%
Lesion Length Treated (mm)	128.1 ± 83.0	163.6 ± 88.1	241.2 ± 59.4	144.0 ± 88.9
Mod/Sev Calcium	70.4%	63.9%	69.4%	100.0%
Stenosis				
Pre-treatment	93.8 ± 10.0	99.8 ± 2.2	96.6 ± 10.1	94.0 ± 10.3
Post-treatment	5.5 ± 9.5	6.0 ± 10.0	6.5 ± 10.8	6.7 ± 11.2
Vessel Preparation				
Atherectomy	4.3%	6.8%	5.9%	4.3%
IVL	5.3%	3.6%	3.0%	8.7%

Secemsky E, on behalf of the ELEGANCE Investigators. 12-month Outcomes for Patients with Complex PAD Treated with Eluvia DES from the ELEGANCE Registry. VIVA 2026 Scientific Sessions, Las Vegas, NV; 2026.



ELUVIA Drug-Eluting Vascular Stent System Indications, Safety, and Warnings

<https://www.bostonscientific.com/eluvia-indications>

**Boston
Scientific**

Advancing science for life™

Interventional Therapies

300 Boston Scientific Way
Marlborough, MA 01752-1234
www.bostonscientific.com

To order product or for more information
contact customer service at 1.888.272.1001.

© 2026 Boston Scientific Corporation
or its affiliates. All rights reserved.

PI-2607407-AA